Inhibition of Neurotoxic Secretory Phospholipases A(2) Enzymatic, Edematogenic, and Myotoxic Activities by Harpalycin 2, an Isoflavone Isolated from Harpalyce brasiliana Benth


Autoria(s): Ximenes, Rafael M.; Rabello, Marcelo M.; Araujo, Renata M.; Silveira, Edilberto R.; Fagundes, Fabio H. R.; Diz-Filho, Eduardo B. S.; Buzzo, Simone C.; Soares, Veronica C. G.; Toyama, Daniela de O.; Gaeta, Henrique H.; Hernandes, Marcelo Z.; Monteiro, Helena S. A.; Toyama, Marcos H.
Contribuinte(s)

Universidade Estadual Paulista (UNESP)

Data(s)

20/05/2014

20/05/2014

01/01/2012

Resumo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Secretory phospholipases A(2) (sPLA(2)) exert proinflammatory actions through lipid mediators. These enzymes have been found to be elevated in many inflammatory disorders such as rheumatoid arthritis, sepsis, and atherosclerosis. The aim of this study was to evaluate the effect of harpalycin 2 (Har2), an isoflavone isolated from Harpalyce brasiliana Benth., in the enzymatic, edematogenic, and myotoxic activities of sPLA2 from Bothrops pirajai, Crotalus durissus terrificus, Apis mellifera, and Naja naja venoms. Har2 inhibits all sPLA(2) tested. PrTX-III (B. pirajai venom) was inhibited at about 58.7%, Cdt F15 (C. d. terrificus venom) at 78.8%, Apis (from bee venom) at 87.7%, and Naja (N. naja venom) at 88.1%. Edema induced by exogenous sPLA(2) administration performed in mice paws showed significant inhibition by Har2 at the initial step. In addition, Har2 also inhibited the myotoxic activity of these sPLA(2)s. In order to understand how Har2 interacts with these enzymes, docking calculations were made, indicating that the residues His48 and Asp49 in the active site of these enzymes interacted powerfully with Har2 through hydrogen bonds. These data pointed to a possible anti-inflammatory activity of Har2 through sPLA(2) inhibition.

Formato

9

Identificador

http://dx.doi.org/10.1155/2012/987517

Evidence-based Complementary and Alternative Medicine. New York: Hindawi Publishing Corporation, p. 9, 2012.

1741-427X

http://hdl.handle.net/11449/381

10.1155/2012/987517

WOS:000308300500001

WOS000308300500001.pdf

Idioma(s)

eng

Publicador

Hindawi Publishing Corporation

Relação

Evidence-based Complementary and Alternative Medicine

Direitos

openAccess

Tipo

info:eu-repo/semantics/article